Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MS-20,Undisclosed
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Microbio's "MS-20" Shows Promise as Add-On Therapy for Ulcerative Colitis
Details : MS-20 is a postbiotic produced through the symbiotic fermentation of multi-strain probiotics. It is being investigated for immunological and gastrointestinal diseases.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : MS-20,Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SNS812
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Oneness Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Pan-COVID New Drug - SNS812 Achieves Superiority in Phase 2 Study
Details : SNS812 achieves statistical significance with clinically meaningful endpoints in the Phase 2 trial and is the only therapeutic with a broad-spectrum efficacy in multiple coronavirus variants.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : SNS812
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Oneness Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MS-20
Therapeutic Area : Immunology
Study Phase : Undisclosed
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
MS-20 on Patients With Ulcerative Colitis(UC)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
June 01, 2021
Lead Product(s) : MS-20
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MS-20
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
June 01, 2021
Lead Product(s) : MS-20
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MS-20
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : MS-20
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MBS
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Postbiotic MBS and Metformin Combination in Patients With T2DM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 20, 2020
Lead Product(s) : MBS
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MS-20
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
October 23, 2020
Lead Product(s) : MS-20
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MB-110
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2015
Lead Product(s) : MB-110
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 13, 2010